GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m., Eastern Time. The Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existin ...

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (t ...

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company ...

Group 1 - AIM ImmunoTech Inc. announced a reverse stock split at a ratio of 1-for-100, effective June 12, 2025 [1] - The primary goal of the reverse stock split is to increase the per-share market price to regain compliance with NYSE American's Listing Qualifications [2] - Stockholders approved the reverse stock split at a Special Meeting on April 30, 2025, and will receive cash for any fractional shares post-split [3] Group 2 - AIM ImmunoTech Inc. focuses on the research and development of therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), an investigational drug with broad-spectrum activity in clinical trials [4]

CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today announced that the Company’s stockholders have approved a proposal to effect a reverse split, which was voted on at the Company’s 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 2025, and that its Board of ...

Core Viewpoint - Artelo Biosciences, Inc. has announced a 6-for-1 reverse stock split to increase the price per share to meet Nasdaq's minimum listing requirement of $1.00 per share, effective June 13, 2025 [1][2]. Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatological issues [3]. - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [3]. Reverse Stock Split Details - The reverse stock split will automatically convert every six shares of the company's common stock into one share, maintaining shareholders' pro-rata ownership [2]. - Post-split, approximately 546,667 shares of common stock will be issued and outstanding [2].

Recently, Opendoor announced that it could seek to complete a reverse stock split within the next few months. While a reverse split is typically bad news for stocks, there is good reason to believe that Opendoor's business could improve significantly over the next year or two. It wasn't too long ago that Opendoor Technologies (OPEN 6.30%) was an extremely popular momentum stock, with a market cap of more than $20 billion at one point. The clear leader in the iBuying industry, Opendoor went public as part of ...

This unstoppable company has split its shares nine times in the last 37 years, but found itself on the chopping block by a pair of billionaire fund managers in the first quarter. There's nothing more valuable on Wall Street than data -- and there's rarely a shortage of it for investors. Between earnings season, which is a six-week period each quarter where most S&P 500 companies report their operating results, and near-daily economic reports from the federal government, it's easy for investors to be overwhe ...

Artificial intelligence (AI) software stocks have been a favorite among growth investors over the last couple of years. As of closing bell on June 6, shares of enterprise software darling Palantir Technologies have gained 69% on the year, making it the top-performing stock in the Nasdaq-100 index. While Palantir appears to be on an unstoppable run, smart investors understand that there are other opportunities at the intersection of artificial intelligence (AI) and software. One AI software company that has ...

Core Viewpoint - Tilray Brands, Inc. announced the approval of a reverse stock split at a ratio of 1-to-10 to 1-to-20, but has paused its implementation to evaluate timing and stock price [1][2]. Financial Structure - In the fiscal quarter ended February 28, 2025, Tilray reduced its total debt by approximately $76 million, resulting in a net debt to trailing twelve-months Adjusted EBITDA of less than 1.0x [3]. - As of the last fiscal quarter, Tilray's cash and marketable securities balance was approximately $250 million, providing financial strength and flexibility for strategic opportunities and acquisitions [3]. Strategic Objectives of Reverse Stock Split - The reverse stock split aims to ensure compliance with Nasdaq listing requirements, align the number of shares with similar companies, attract institutional shareholders, and potentially save up to $1 million annually in costs associated with stockholder meetings [7].